SB17170 Phase 2 Trial in IPF Patients

NCT06747923 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

IPF
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)

Interventions

DRUG: SB17170
DRUG: Placebo

Sponsor

SPARK Biopharma